MktsMarkets

Summit Therapeutics Inc.
NASDAQ: SMMTKey statistics
SMMT News
Stories mentioning SMMT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | |||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Operating Expenses | ||||||||
| Research & Development | 132,618 | 51,265 | ||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | 195,212 | 224,925 | 234,211 | 568,437 | 66,851 | 65,614 | 58,378 | 59,617 |
| Operating Income (Loss) | (65,614) | (58,378) | (59,617) | |||||
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 0.00 | (53.00) | 0.00 | 0.00 | 0.00 | |||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (189,424) | (219,172) | (231,793) | (565,708) | (62,913) | (61,203) | (56,254) | (60,385) |
| Earnings Per Share (Basic) | (0.24) | (0.29) | (0.31) | (0.76) | (0.09) | (0.09) | (0.08) | (0.09) |
| Earnings Per Share (Diluted) | (0.24) | (0.29) | (0.31) | (0.76) | (0.09) | (0.09) | (0.08) | (0.09) |
| Weighted Average Shares Outstanding (Basic) | 775,458 | 747,702 | 743,416 | 742,615 | 738,076 | 718,542 | 726,656 | 707,905 |
| Weighted Average Shares Outstanding (Diluted) | 775,458 | 747,702 | 743,416 | 742,615 | 738,076 | 718,542 | 726,656 | 707,905 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About SMMT
Summit Therapeutics Inc. (NASDAQ: SMMT) is a stock listed on the Nasdaq Stock Market under the ticker symbol SMMT. It last traded at $14.15 (Nov 13, 2026, 4:00 PM ET), down 6.1% on the day. That gives Summit Therapeutics a market capitalisation of $11.3B.
Over the past 52 weeks SMMT has traded between $12.07 and $29.23.
For the quarter ended Mar 31, 2026 it reported a net loss of $189.4M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$189.4M |
| Dec 31, 2025 | — | -$219.2M |
| Sep 30, 2025 | — | -$231.8M |
| Jun 30, 2025 | — | -$565.7M |
From Summit Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…